0.00Open0.00Pre Close0 Volume0 Open Interest1.00Strike Price0.00Turnover0.00%IV51.46%PremiumDec 20, 2024Expiry Date0.00Intrinsic Value100Multiplier22DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type--Delta--Gamma41.20Leverage Ratio--Theta--Rho--Eff Leverage--Vega
Akebia Therapeutics Stock Discussion
3 mins ago
Akebia Therapeutics Signs Commercial Supply Contract With Leading Dialysis Organization to Enable Access to Vafseo® (Vadadustat) for Patients on Dialysis! Expected to be available in USA in January 2025
Designed to help dialysis organizations incorporate new treatments into their practices, TDAPA provides two years of reimbursement in addition to the ESRD bundled rate
A HCPCS code has also been assig...
Akebia Therapeutics Inc - Contract Enables Prescription of Vafseo for Dialysis Patients From Jan 2025
No comment yet